CCI_White
    POC (7)
    Partner With Us!
    Complete list of Cleveland Clinic Innovations Portfolio companies

     

    We welcome potential partners to learn more about our new companies featuring next-generation medical products. 

     

    Cleveland Clinic Innovations' goal is to support venture-stage companies in their efforts to commercialize Cleveland Clinic intellectual property and positively impact patient care. 

     

    Companies Currently Fundraising

    • Turning visitors into leads.
    abcon
    Abcon_New-Cancer-Treatment-Being-Developed-for-Incurable-Lymphoma (1)

    Abcon Therapeutics

    Field: T-cell mediated diseases and related cancers, with initial focus on T-Cell Lymphoma (TCL).


    Mode and MOA: First product, ATX101, is a fully humanized monoclonal antibody-drug conjugate (ADC) that targets CD6, an established T-Cell specific receptor.


    Data: ATX101 has been highly effective in treating preclinical models of TCL, demonstrating tumor shrinkage and inhibition of tumor metastasis.


    Current development status: IND-enabling tox studies.


    IP: Exclusive license to Cleveland Clinic-developed mAbs and ADCs; Issued and pending patent applications covering composition of matter and methods of treating T-cell mediated disease.


    Raise: Active Series A Round.


    mobius-care
    1710201529689

    Mobius Care

    • Field: Inflammatory bowel disease (IBD).

    • Mode and MOA: Novel AI digital pathology tool for stratification of IBD patients to existing drugs and candidates under development.

    • Data: In vitro and in vivo proof of concept established.

    • Current development status: In vivo validation.

    • IP: Exclusive option to Cleveland Clinic - and Washington University-developed intellectual property; Pending patent applications covering diagnostic methodologies.
    •  
    • Raise: Active Seed Round.

    neurotherapia
    f2ff6e_47848a981e684d5f9f57af0b6743f01e~mv2 (1)

    Neurotherapia

    Field: Neuroinflammation for CNS disease; initially targeting Alzheimer’s Disease (AD).


    Mode and MOA: Small molecule therapies targeting microglial cells; Lead compound NTRX-07 is a CB2 agonist shown to reduce neuroinflammation.


    Data: Phase 1 safety studies in AD completed successfully.


    Current development status: Ready for phase 2 clinical studies.


    IP: Exclusive license to Cleveland Clinic -developed small molecules; Issued and pending patent applications covering composition and method of use for treating neuroinflammation.


    Raise: Active Series B Round.

    • Turning visitors into leads.

    zenha-therapeutics
    Heart

    Zehna Therapeutics

    Field: Cardiometabolic diseases with initial focus on cardiovascular disease (CVD) and chronic kidney disease (CKD).


    Mode and MOA: Small molecules inhibit gut microbial enzyme CutC, preventing molecular conversion to trimethylamine N-oxide (TMAO) – a metabolite connected to CVD and CKD risk.


    Data: In vivo proof-of-concept established.

    Current development status: Expect IND-ready in 2024.

    IP: Excusive license to Cleveland Clinic -developed small molecules; Issued and pending patent applications covering compositions and methods of use.

    Raise: Active Series A Round.

    Co-Creation Opportunities

    PSMA

    Field: Radiotheranostics for treatment of prostate cancer.


    Mode and MOA: Next-generation PSMA-targeting radioligand has higher specificity than on-market prostate cancer radiotherapies, reducing side effects.


    Data: In vivo proof-of-concept established.


    Current development status: GMP manufacturing completed and released under CoA; IND-enabling stability and acute toxicity studies in progress; Phase 0 study ready expected 2024.


    IP: Excusive option to Cleveland Clinic -developed compounds; Issued and pending patent applications covering compositions and methods of use.


    Ask: Seeking co-investment or co-development partners.

     

    prostate

    ComAb

    Field: Complement-mediated diseases.


    Mode and MOA: Pipeline of monoclonal antibody (mAb) therapeutics targeting various aspects of the complement cascade; lead programs targeting C6, a key protein in membrane attack complex (MAC) formation.

    Data: In vivo proof-of-concept established.

    Current development status: Lead program fully humanized and entering IND-enabling studies.


    IP: Cleveland Clinic has filed patent applications covering compositions and methods of use.

    Ask: Seeking co-investment or co-development partners.

    prostate (1)

    Get In Touch:

    Click Here

    or
    Call:

    216.444.5757

    Shape Image One
    Shape Image One
    Shape Image One